Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intrapleural TVEC and Nivolumab for Malignant Pleural Effusion
NCT03597009Phase 2Terminated
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Mar 2019
- Primary completion
- Feb 2020
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
A Phase 2 trial of talimogene laherparepvec in malignant pleural effusion (MPE), sponsored by UNC Lineberger Comprehensive Cancer Center. Started Mar 2019; status: terminated.
02
Drugs
talimogene laherparepvec
03
Conditions
malignant pleural effusion (MPE)
Beyond the preview
Go deeper on NCT03597009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03597009.